Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNoxopharm Ltd

Noxopharm Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.035 AUD 0.00(0%)
Last update at 2026-11-06T04:57:00Z
VOLUME
546819
Market Cap
10.75M

Momentum Score

…

Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.04
High
52 Week Price Range
0.03
Low
0.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Noxopharm is an Australian clinical-stage company developing small-molecule and immune-modulating therapies for cancer as adjuncts to standard treatments. Long-term growth may be driven by clinical trial outcomes, regulatory approvals and licensing or partnership deals that could enable wider use of its compounds.
Key risks include high clinical and regulatory uncertainty, ongoing financing needs that could dilute shareholders, and strong competition in oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
1.43M
Revenue Per Share
0.01
Gross Profit TTM
-0.52M
Debt / Equity
-1.25
ROE
-343.56%
Net Debt
4.28M
ROCE
93.73%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.46M -4.88M -5.98M -15.06M -18.67M
Net income -4.46M -4.88M -3.58M -15.06M -18.74M
Selling general administrative 0.80M 0.92M 1.04M 4.88M 6.58M
Selling and marketing expenses 2.10M 0.02M 0.06M 0.19M 0.10M
Gross profit 1.45M -1.45M -0.53M - -
Reconciled depreciation - - 0.00M 0.15M 0.26M
Ebit -3.40M -5.39M -5.95M -14.96M -18.59M
Ebitda -3.40M -5.38M -5.95M -14.80M -18.33M
Depreciation and amortization 0.00M 0.00M 0.00M 0.15M 0.26M
Operating income -3.40M -9.65M -7.54M -14.96M -18.59M
Other operating expenses 4.85M 12.47M 9.94M 16.60M 15.21M
Interest expense 1.16M 0.50M 0.03M 0.04M 0.08M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - 0.49M 0.01M 4.49M 0.05M
Net interest income - - -0.02M 0.04M -0.03M
Income tax expense -1.43M -2.82M -2.40M 1.60M 0.08M
Total revenue 1.45M 2.82M 2.40M 6.07M 5.45M
Total operating expenses 4.85M 8.21M 7.00M 16.60M 15.21M
Cost of revenue 0.00M 4.27M 2.94M - -
Total other income expense net -1.06M 4.77M 1.56M 1.50M -0.08M
Net income from continuing ops - - -3.58M -15.06M -18.67M
Net income applicable to common shares - -4.88M -3.58M -15.06M -18.67M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1.84M 4.58M 6.78M 10.13M 26.59M
Other current assets 0.03M 0.08M 0.04M 0.00M 0.46M
Total liab 5.48M 3.89M 1.29M 1.06M 2.48M
Total stockholder equity -3.65M 0.69M 5.50M 9.07M 24.12M
Other current liab 0.35M 0.94M 0.60M 0.51M 1.31M
Common stock 74.64M 74.64M 74.64M 74.64M 74.64M
Capital stock - - - 74.64M 74.64M
Retained earnings -78.48M -74.65M -70.07M -72.06M -58.80M
Other liab - - - 0.09M 0.19M
Other assets - - - 0.00M 0.12M
Cash 0.29M 1.55M 2.32M 3.01M 14.01M
Cash and equivalents - - - 0.00M 8.00M
Total current liabilities 5.46M 3.87M 1.25M 0.96M 2.28M
Net debt 4.28M 0.92M -2.32M -3.01M -13.85M
Short term debt 4.57M 2.48M - 0.00M 0.16M
Short long term debt total 4.57M 2.48M - - 0.16M
Other stockholder equity - - - 6.50M 8.29M
Property plant equipment - - - 0.01M 0.22M
Total current assets 1.83M 4.58M 4.77M 9.16M 20.83M
Long term investments - - - 0.96M 5.42M
Net tangible assets - - - 9.07M 24.12M
Net receivables 1.51M 2.95M 2.40M 6.08M 5.21M
Inventory - - - - 1.15M
Accounts payable 0.54M 0.45M 0.65M 0.45M 0.81M
Accumulated other comprehensive income 0.20M 0.70M 0.93M 6.50M 8.29M
Non currrent assets other - - - - 0.12M
Non current assets total 0.00M 0.00M 2.02M 0.97M 5.76M
Capital lease obligations - - - - 0.16M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - - 0.12M -
Change to liabilities - - - -1.08M -4.33M
Total cashflows from investing activities - 2.48M 0.00M 0.12M 0.12M
Net borrowings - - 2.00M -0.18M -0.23M
Total cash from financing activities 1.45M 2.60M 0.00M -0.18M 0.98M
Change to operating activities - - - -0.18M -0.08M
Net income -4.46M -4.88M -3.58M -15.06M -18.74M
Change in cash -1.26M -0.77M -0.69M -11.00M -12.79M
Begin period cash flow 1.55M 2.32M 3.01M 14.01M 26.80M
End period cash flow 0.29M 1.55M 2.32M 3.01M 14.01M
Total cash from operating activities -2.71M -5.82M -0.68M -10.95M -18.48M
Issuance of capital stock - - - - 1.20M
Depreciation 0.00M 0.00M 0.00M 0.15M 0.26M
Other cashflows from investing activities - 2.48M 0.00M 0.12M 0.12M
Change to inventory - - - 1.15M -0.83M
Change to account receivables - -0.57M 3.70M -0.48M 0.18M
Sale purchase of stock - - - 0.00M 1.20M
Other cashflows from financing activities 1.45M - -2.00M -0.18M -0.23M
Change to netincome - - - 4.55M 9.74M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - -0.45M 3.73M 5.12M 5.95M
Stock based compensation - 0.06M - - -
Other non cash items 1.74M -0.55M -0.84M - 18.48M
Free cash flow -2.71M -5.82M -0.68M -10.95M -18.48M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NOX
Noxopharm Ltd		 -
-%		 0.04 - - 7.53 38.97 -1.16
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 -9.86

Profile*

Noxopharm Ltd

Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.

60 Linksley Ave, Glenhaven, NSW, Australia, 2156

61 2 9144 2223

https://www.noxopharm.com

Name Title Year Born
Dr. Gisela Mautner CEO, Exec. MD, Chief Medical Officer & Director NA
Mr. Shawn Van Boheemen Chief Financial Officer NA
Ms. Jeanette Bell Ph.D. Chief Operating Officer NA
Dr. John Wilkinson B.Sc., Ph.D. Chief Scientific Officer of Oncology NA
Dr. Olivier Laczka B.S., M.Sc., Ph.D. Chief Scientific Officer of Inflammation NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA
Mr. Shawn Van Boheemen FCPA Chief Financial Officer NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…